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Abstract
Objective—To elucidate the mechanisms by which a cash incentive intervention increases 
retention in prevention of mother-to-child transmission (PMTCT) services.
Methods—We used data from a randomized controlled trial in Kinshasa, Democratic Republic of 
Congo. Perceptual factors associated with loss-to-follow-up (LTFU) through six weeks postpartum 
were first identified. Then, binomial models were used to assess interactions between LTFU and 
identified factors, and the cash incentive intervention.
Results—Participants were less likely to be LTFU if they perceived HIV as a “very serious” 
health problem for their baby vs. not (risk difference [RD], −0.13; 95% confidence interval [CI], 
−0.30, 0.04), if they believed it would be “very likely” to pass HIV on to their baby if they did not 
take any HIV drug vs. not (RD, −0.15; 95% CI, −0.32, 0.02), and if they anticipated that not 
having money would make it difficult for them to come to clinic vs. not (RD, 0.12; 95% CI, −0.07, 
0.30). The effect of each of the three factors on LTFU was antagonistic to that of receiving the 
cash incentive intervention. The excess risk due to interaction between the cash incentive 
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intervention and the anticipated difficulty of “not having money” to come to clinic was exactly 
equal to the effect of removing this perceived barrier (excess risk due to interaction, −0.12; 95% 
CI, −0.35, 0.10).
Conclusions—Our analyses show that cash transfers improve retention in PMTCT services 
mainly by mitigating the negative effect of not having money to come to the clinic.
Keywords
Conditional cash transfers; PMTCT; retention in care; mechanism; DR Congo
INTRODUCTION
At the end of 2014, 77% of HIV-infected pregnant women in the 21 Global Plan priority 
countries in sub-Saharan Africa were receiving antiretrovirals for their own health or for the 
prevention of mother-to-child transmission (PMTCT).1 Moreover, there has been a rapid 
shift to the 2013 WHO recommendations of lifelong antiretroviral therapy (ART) for all 
HIV-infected pregnant and breastfeeding women regardless of their clinical or immune 
status (Option B+) 2. If implemented optimally, these guidelines could lead to mother-to-
child transmission (MTCT) rates below 5% in a breastfeeding population and below 2% in a 
non-breastfeeding population 3. Recent data from the Promise Study showed that with 
Option B+, a transmission rate as low as 0.5-0.6% can be achieved by age 14 days 4.
To ensure maximum benefit from ART for themselves and for PMTCT, HIV-infected 
pregnant women have to adhere to a continuum of services often referred to as the “PMTCT 
cascade” 5. The cascade includes attendance of regular clinic visits (at a minimum for ART 
refills), delivery in a health facility, and testing of the HIV-exposed infant (HEI) at six 
weeks, at nine months, and at the end of breastfeeding (between 18-24 months). Yet, data 
from early implementation of Option B+ in Malawi showed that about one in six pregnant 
women initiated on ART at antenatal care (ANC) registration do not return to the clinic after 
their initial visit 6. In addition, a recent meta-analysis of women lost to follow-up (LTFU) 
across the “PMTCT cascade” found that 49% of HIV-infected pregnant women are LTFU 
between ANC registration and delivery, and 34% of mother-infant pairs are LTFU within 
three months of delivery 7. Although the MTCT rate was 5% at six weeks in the 21 priority 
countries in sub-Saharan Africa in 2014, as a result of high rate of LTFU, it rose to 14% by 
the end of breastfeeding when many of the mothers are no longer on ART 8.
Identification of effective and scalable strategies to improve retention along the PMTCT 
cascade and improve uptake of HIV services is at the forefront of PMTCT optimization 
efforts. In a recent randomized controlled trial, we found that providing newly-diagnosed 
HIV-infected women with small and increasing cash incentives, on the condition that they 
attended scheduled clinic visits and received available PMTCT services, significantly 
increased the proportion of women who were retained in care and received available 
PMTCT services through six weeks postpartum 9,10. The intervention choice was informed 
by an important finding in the behavioral economics literature that many individuals have 
present-biased preferences, whereby they place disproportionate weight on present costs and 
benefits relative to those in the future.11 Thus, consistent with the Health Belief Model's12 
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elements of “perceived risk,” “perceived benefit,” and “perceived barriers,” it was 
hypothesized that though there may be strong health incentives (e.g., desire to ovoid MTCT) 
for HIV-infected pregnant women to engage in HIV care and treatment, women may place 
substantial weight on the immediate costs of PMTCT, which include the financial and 
opportunity costs of attending regular clinic visits, and heavily discount the delayed 
benefits.13,14 Verification of the mechanisms by which cash incentive interventions increase 
desired PMTCT outcomes would 1) enhance our understanding of how these interventions 
work and 2) improve our ability to design and scale up similar interventions for PMTCT and 
other health and social issues.
To elucidate the mechanisms by which a cash incentive intervention increases desired 
PMTCT outcomes using a modified Health Belief Model as conceptual framework (Figure 
1), we examined the associations between perceptual factors (perceived severity of HIV, 
perceived MTCT susceptibility/risk, perceived PMTCT benefit, perceived barriers and self-
efficacy to access and use PMTCT services) and retention in care. We also assessed the 
potential interactions between 1) perceptual factors found to be associated with retention in 
care and 2) the effect of a conditional cash incentive intervention on the same outcome.
METHODS
Study design and study population
This is an analysis of data from a randomized controlled trial that was conducted in 
Kinshasa, the Democratic Republic of Congo (DRC). Between April 2013 and August 2014, 
433 newly-diagnosed HIV-infected women, ≤32 weeks pregnant, registering for ANC at one 
of 89 clinics during the enrollment period were recruited and randomized to receive either 
the standard of care or the standard of care plus small and increasing cash payments. These 
payments started at $5 and increased by $1 each month on the condition that the woman 
attended scheduled clinic visits and provided a blood sample for a CD4 count, accepted 
referral for ART if referred, delivered in a health facility, and at six weeks postpartum 
provided a blood sample for early infant HIV diagnosis. A detailed description of the 
intervention, and results of the analysis of primary outcomes showing that the intervention 
resulted in significantly higher retention along the PMTCT cascade and better uptake of 
available services, have been reported.
Perceptual factors and measurements
At enrollment into the study, which occurred between two to four weeks after registration 
for ANC and HIV diagnosis, participants were interviewed using a structured questionnaire 
to collect information on perceived HIV severity, perceived MTCT susceptibility/risk, 
perceived PMTCT benefits, perceived difficulties and barriers accessing PMTCT services, 
and perceived self-efficacy to access and adhere to clinic visits and PMTCT services (see 
Figure 1 for the conceptual model). All survey questions for the perceived factors had 
Likert-style scale response options (e.g., “very likely,” “somewhat likely,” “somewhat 
unlikely,” “very unlikely,” “don't know,” and “refuse to answer”). The questions, response 
options and the final coding of those responses are summarized in Table 1.
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Outcome variables
The main outcome considered in this analysis was LTFU – not in care at six weeks 
postpartum with unknown whereabouts (participants who were dead, or who did not return 
to the clinic because they experienced a poor pregnancy outcome but could still be reached, 
were classified as not in care but not as LTFU).
Statistical analysis
Identification of perceptual factors associated with LTFU—Using data from 
participants randomized to the control group (to avoid any mixing of effect), we examined 
the associations of the measured perceptual factors with LTFU by comparing the proportion 
of participants LTFU by six weeks postpartum across categories of perceptual variables. 
Multivariate logistic regression models including all of the perceptual factors were used to 
identify factors that were independently predictive of LTFU and to estimate odds ratios (OR) 
and 95% confidence intervals (CI) assessing the strength of their associations with the 
outcome. Perceptual variables found to be significantly associated (alpha=0.20) with LTFU 
after adjustment for all other factors considered as well as wealth index were retained for the 
evaluation of interaction with the cash incentive intervention. Wealth index was included in 
the model because sub-group analysis of the primary trial outcomes showed that the effect of 
the cash intervention was particularly strong for poorer women.9 Wealth index was 
determined using principal component analysis. The model for this factor analysis included 
years of education, average number of household members per room (an indication of 
crowding), number of sleeping beds in the household, types of household water source 
(communal or private pipe), cooking fuel type (electrical stove, or wood/charcoal), and 
ownership status for several durable assets. The first component explained 27% of the 
variability in the data. The factor score was categorized into upper (two richest quintiles), 
middle (third quintile), and lower (two poorest quintiles) categories.
Modification of the effects of identified perceptual factors on LTFU by the 
cash incentive intervention—To assess potential synergism or antagonism between 
perceptual factors found to be significantly and independently associated with LTFU and the 
cash incentive intervention, log-linear risk models were used to estimate the risk difference 
(RD) measuring the individual and joint effects of the conditional cash incentive intervention 
and the perceptual factor on the outcome. The likelihood ratio test was used to assess RD 
modification, and excess risk due to interaction (interaction contrast [IC] and 95% CI) was 
used to assess for synergism or antagonism. IC is the difference between the observed RD 
comparing the doubly-exposed category with the doubly-unexposed category, and the 
expected RD comparing the same two groups assuming additivity (without the interaction 
term) should be equal to zero in the absence of RD modification. All analyses were 
completed using SAS 9.3 (SAS Institute Inc., Cary, NC). All tests were two-sided and used a 
0.20 significance level unless otherwise indicated.
The study is approved by the Institutional Review Board of the Ohio State University and 
the Ethical Committee of the Kinshasa School of Public Health. This parent trial is 
registered at ClinicalTrials.gov, number NCT01838005.
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RESULTS
Perceptual factors
Overall, most participants perceived HIV as a “very serious” health problem for themselves 
(78.5%, 340/433) and for their infants (84.3%, 365/433) (Table 2). The perception of MTCT 
susceptibility/risk was also high; 83.6% (362/433) of participants responded that it was 
“very likely” they will pass HIV on to their baby if they did not take any HIV drug. 
Similarly, the perceived benefit of PMTCT medication was also very high; 84.8% (367/433) 
of participants believed it would be “very unlikely” that they will pass HIV on to their baby 
if they take all their HIV drugs. Over 90% (391/433) of participants stated they were “very 
confident” to be able to come to clinic every month to collect their HIV drugs and get 
checked; accordingly, 83.8% (363/433) anticipated that it would be “very easy/not at all 
difficult” for them to come to clinic. The anticipated difficulties included “transportation” 
for 15.9% (69/433) and “not having money” for 11.6% (50/433) of respondents. Virtually all 
participants, 98.4% (426/433), stated that it was “very likely” they would take all of their 
medication every day without missing any doses.
Association between perceptual factors and LTFU
In bivariate analysis, perceived MTCT susceptibility/risk was the strongest predictor of 
LTFU; participants who perceived passing HIV on to their baby was “very likely” if they did 
not take their HIV drugs were strongly and statistically less likely to be LTFU at six weeks 
postpartum compared to those who did not perceive the risk of transmission as “very likely” 
(OR= 0.44; 95% CI, 0.19, 0.99) (Table 3). Participants who perceived HIV to be a serious 
health problem for their infants (OR, 0.50; 95% CI, 0.21, 1.14) were also less likely to be 
LTFU at six weeks postpartum compared to women who did not perceive HIV as a serious 
health problem. On the other hand, compared to participants who responded “nothing” to the 
question “what makes it difficult for you to come to the clinic to receive your treatment?” 
those who responded “not having money” were about twice as likely to be LTFU (OR, 1.90; 
95% CI 0.75, 4.84).
In a multivariate logistic model, women who perceived it as “very likely” that they will 
transmit HIV to their baby if they did not take any HIV drug remained statistically less 
likely to be LTFU (adjusted OR [aOR], 0.39; 95% CI, 0.14, 1.08). Though not statistically 
significant, HIV-infected women who perceived HIV to be a serious health problem for their 
baby were also less likely to be LTFU at six weeks postpartum (aOR, 0.55; 95% CI, 0.18, 
1.65). Accordingly, perceived lack of benefit of PMTCT medication was associated with 
LTFU. Women who responded that it was “very unlikely” that they will pass HIV to their 
baby if they take all their HIV drugs were twice as likely to be LTFU (aOR, 2.01 95% CI, 
0.64, 6.30). Believing that “not having money” will make it difficult to come to the clinic 
was the only anticipated barrier associated with an increased tendency of LTFU (aOR, 1.83; 
95% CI 0.67, 5.02).
Modification of the effects of identified perceptual factors on LTFU by the 
cash incentive intervention—Table 4 presents the RDs and 95% CIs for LTFU for each 
exposure (perceptual factors and cash incentives) individually and jointly, as well as the 
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excess RDs due to interaction (IC) and their 95% CIs. Perceiving HIV as a “very serious” 
health problem for their baby vs. not was associated with a 13% decrease in the proportion 
of women LTFU by six weeks postpartum (RD, −0.13; 95% CI, −0.30, 0.04) among women 
who did not receive the cash incentive intervention. Among women who did not perceive 
HIV as a “very serious” health problem for their baby, receiving the cash incentive was 
associated with a 23% (RD, −0.23; 95% CI, −0.41, −0.04) reduction in the proportion of 
participants LTFU. The effects of the two exposures were not additive for participants who 
perceived HIV as a “very serious” health problem and received the cash incentive (RD, 
−0.20; 95% CI, −0.37, −0.03). The antagonistic excess RD due to interaction (IC, 0.16; 95% 
CI, −0.04, 0.35). Similar antagonism was observed for the perception that it will be “very 
likely” to pass HIV on to the baby if one did not take any HIV drug.
Anticipating that “not having money” will make it difficult to come to clinic to receive 
treatment, though not statistically significant, was associated with a 12% (95% CI, −7%, 
30%) increase in the proportion LTFU at six weeks postpartum among participants who did 
not receive the cash incentive (compared to participants who reported “nothing” when asked 
about barriers to clinic attendance). Providing women in this group with a cash incentive 
perfectly antagonized the negative effect of “not having money” on LTFU (IC, −0.12; 95% 
CI, −0.35, 0.10).
DISCUSSION
If ART is started at an early stage of pregnancy and continued uninterrupted throughout 
breastfeeding, the risk of HIV transmission from mother to child decreases to almost zero.4 
But without novel strategies to increase retention in and adherence to PMTCT services, the 
goal of an AIDS-free generation is unlikely to be achieved. In this study, we examined the 
mechanisms through which a cash incentive intervention recently tested by our group in a 
randomized controlled study increases retention in care.
As hypothesized during design of the study, our analysis showed that HIV-infected pregnant 
women who perceived HIV as a “very serious” health problem for their baby (perceived 
severity of HIV), and perceived that they will “very likely” pass HIV on to their baby if they 
did not take their drugs (perceived benefit of PMTCT), were more likely be have been 
retained in care through six weeks postpartum. Our results are in agreement with previous 
studies showing that better PMTCT knowledge15 as well as greater understanding and belief 
in the effectiveness of ART16 are positively associated with higher adherence to PMTCT 
services. Interestingly, the observed antagonism between the cash incentive intervention and 
1) the perception of HIV as a very serious health problem for the baby and 2) believing that 
it will be very likely that HIV will be transmitted to the baby if one does not take any HIV 
drugs suggests a competitive mechanism of action as represented in the conceptual 
framework. Consistent with the Prospect Theory,17 this observation suggests that 
interventions which combine 1) relatively short-term cash incentives to keep asymptomatic 
pregnant women who are likely to be LTFU and 2) an effective education program to 
improve women's understanding of HIV risk for themselves and for the baby may achieve 
meaningful and sustained retention.
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Lack of financial support is a known risk factor for poor ART adherence among HIV-
infected women 18. Our finding that provision of a small cash incentive to those women 
completely reverses the negative effect of “not having money” on LTFU is a confirmation 
that there are real financial barriers to accessing HIV care, at least in maternal and child 
health clinics where PMTCT programs are implemented despite HIV care itself being 
provided free of charge. In fact, in most countries in sub-Sahara Africa, hospitals and clinics 
are funded on a fee-per-service basis, and HIV-infected women have to be able to pay for 
their antenatal visits registration and delivery costs, as well as register for the well-baby 
clinic visit in the postpartum period to be able to continue to have access to the clinic at each 
of those steps.19 The magnitude and structure of those fees varies by clinic and might 
explain why some women switch clinics during and after pregnancy.9
The observation of a negative effect of “not having money” on retention also has 
implications for determination of the magnitude of the cash incentive. It has been suggested 
that incentive magnitude be dependent on the opportunity cost incurred by the behavior 
change. A systematic review of the use of financial incentives in treatments for obese and 
overweight persons found evidence of very weak trends in favor of using amounts greater 
than 1.2% of personal disposable income.20 However, while the optimal size and structure of 
incentive payments remain important questions to be addressed empirically, this finding 
suggests that in areas where fee for service is in place, they must be taken into account when 
determining the opportunity costs of attending clinic visits.
This is the first study to examine the mechanisms by which a cash incentive intervention 
achieves the desired outcomes of retention in care among newly-diagnosed HIV-infected 
pregnant women. The study used data from a randomized controlled trial to test hypotheses 
that informed the design of the intervention. Despite the potential risk of misreporting the 
perceptual factors considered in this analysis, the fact that interviews were conducted before 
participants were assigned to randomization groups eliminates any potential for differential 
misreporting by study group or outcome level. However, because the study was not powered 
for this specific analysis, some estimates are unstable with wide confidence intervals.
In conclusion, our analyses show that cash transfers improve retention in PMTCT services 
mainly by mitigating the negative effect of not having money to come to the clinic. In 
designing financial incentive interventions to improve retention in PMTC services, the 
minimum amount proposed should be at least equal to the cost of attending clinic visits.
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Figure 1. Conceptual model for conditional cash transfer intervention for retention in care and 
uptake of prevention of mother-to-child prevention services
The model is based on Health Belief Model 11; MTCT = mother-to-child transmission of 
HIV, PMTCT = prevention of mother-to-child transmission of HIV
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Table 1
Perceptual factors considered, questions used to measure perceptual factors, and final variable coding
Perceptual factors Question Response coding
Perceived Severity of HIV How serious a health problem is HIV for you 
personally? Would you say that it is:
Very serious 1 index
Somewhat serious
Not very serious
Not at all serious
Don't Know
Refuse to answer
0 referent
Now think about your baby. How serious a 
health problem would it be if your baby had 
HIV? Would you say it would be:
Very serious 1 index
Somewhat serious
Not very serious
Not at all serious
Don't Know
Refuse to answer
0 referent
Perceived MTCT susceptibility/risk How likely or unlikely do you think it is that 
you will pass HIV on to your baby if you do 
not take any HIV drug? Would you say it is:
Very likely 1 index
Somewhat likely
Somewhat unlikely
Very unlikely
Don't Know
Refuse to answer
0 referent
Perceived PMTCT benefits How likely or unlikely do you think it is that 
you will pass HIV on to your baby if you do 
take all your HIV drugs as indicated by the 
nurse? Would you say it is:
Very likely 1 index
Somewhat likely
Somewhat unlikely
Very unlikely?
Don't Know
Refuse to
0 referent
Perceived difficulties to accessing 
PMTCT services
How difficult or easy will it be for you to 
come to the clinic to collect your HIV drugs 
and get check? Would it be:
Not at all difficult/very 
easy
1 index
A little difficult, or 
Somewhat difficult
Very difficult
Don't Know
Refuse to answer
0 referent
Perceived barriers to accessing PMTCT 
services
What makes it difficult for you to come to the 
clinic to receive your treatment? (check all 
that apply)
Transportation Nothing 
(referent)
Transportation
Not having 
money
Other
No Childcare
Takes too much time
Husband/partner won't 
allow
Other_________
Perceived self-efficacy to adhere to 
PMTCT medicines
How confident are you that you will be able to 
come to the clinic every month to collect your 
HIV drug? Would you say you are:
Very confident 1 index
Somewhat confident
A little confident, or Not 
at all confident
Don't Know
Refuse to answer
0 referent
How confident are you that you will be able to 
continue to come to this clinic to receive your 
HIV drugs after given birth? Would you say 
you are:
Very confident 1 index
Somewhat confident
A little confident, or Not 
at all confident
Don't Know
Refuse to answer
0 referent
How likely is it that you will take your 
medication everyday without missing any 
doses? Is it:
Very likely 1 index
Somewhat likely
Somewhat unlikely
Very unlikely?
Don't Know
0 referent
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Perceptual factors Question Response coding
Refuse to answer
Anticipated regret if baby infected Imagine that your baby contracted HIV during 
pregnancy or birth, and that you did not 
receive HIV treatment, which could have 
prevented your baby from contracting HIV. 
How much would you regret that you did not 
get HIV drug? Would you:
Regret it a great deal 1 index
Regret it a moderate 
amount
Regret it a little, or Not 
regret it all?
Don't Know
Refuse to answer
0 referent
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Table 2
Perceptions of HIV and mother-to-child transmission risk among 433 newly-identified HIV-infected women in 
Kinshasa, Democratic Republic of Congo
N (%)
How serious a health problem is HIV for you personally?
Very serious 340 (78.5)
Other 93 (21.5)
Now think about your baby. How serious a health problem would it be if your baby had HIV?
Very serious 365 (84.3)
Other 68 (15.7)
How likely or unlikely do you think it is that you will pass HIV on to your baby if you do not take any HIV drug?
Very likely 362 (83.6)
Other 71 (16.4)
How likely or unlikely do you think it is that you will pass HIV on to your baby if you do take all your HIV drugs as 
indicated by the nurse?
Very unlikely 367 (84.8)
Other 66 (15.2)
How difficult or easy will it be for you to come to the clinic to collect your HIV drugs and get checked?
Not at all difficult/very easy 363 (83.8)
Other 70 (16.2)
How confident are you that you will be able to come to the clinic every month to collect your HIV drugs?
Very confident 391 (90.3)
Other 42 (9.7)
How likely is it that you will take your medication every day without missing any doses?
Very likely 426 (98.4)
Other 7 (1.6)
Imagine that your baby contracted HIV during pregnancy or birth, and that you did not receive HIV treatment, which 
could have prevented your baby from contracting HIV. How much would you regret that you did not get HIV drugs?
Regret it a great deal 409 (94.5)
Other 24 (5.5)
What makes it difficult for you to come to the clinic to receive your treatment?
Nothing 274 (63.3)
Transportation 69 (15.9)
Not having money 50 (11.6)
Other 40 (9.2)
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